Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
Opens in a new tab or window In patients with severe metabolic dysfunction-associated steatohepatitis (MASH), the investigational drug efruxifermin significantly improved fibrosis without ...
Last week's survey by the British Potato Council revealed that we prefer mash to chips. So is this good news for our health? Nutritionally speaking, both mash and chips are good sources of energy ...
When it comes to potatoes, mashed is always a pretty good option - especially during the colder months. After all, they're warm, comforting and totally delicious. They make a great side dish for a ...